Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 29 March 2024, 14:19 HKT/SGT
Share:
    

Source: Eisai
Eisai's Brain Health Self-Check Tool "NouKNOW" is Certified as "ME-BYO BRAND" by Kanagawa Prefecture

TOKYO, Mar 29, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that “NouKNOW®”, Eisai’s self-check tool for brain health, was certified as a “ME-BYO BRAND” by Kanagawa prefecture.

About ”ME-BYO BRAND”

“ME-BYO BRAND”, is a certification granted to excellent products/services associated with pre-symptomatic diseases by Kanagawa Prefectural Government in an effort to raise awareness toward pre-symptomatic diseases and promote commercialization of endorsed products/services. It recognizes products/services that contribute to the visualization of pre-symptomatic diseases in the areas of lifestyle, life functions, mental health/stress, and cognitive function, which lead to changes in the awareness and behavior of Kanagawa prefecture residents.

“NouKNOW”, a Self-Check Tool for Brain Health

NouKNOW (non-medical device) is a tool that uses a simple card test using a PC, tablet or smartphone device to perform tests evaluating psychomotor function, attention, learning and memory, and working memory. The results screen displays quantified indicators of brain performance, such as “memorization”, “cognition”, and “decision”, along with lifestyle advice. This digital tool allows users to self-assess independently and in a short time frame (approx. 15 minutes), enabling regular assessments in instances such as daily life and health checkups. It has been adopted by a number of medical and research institutions, municipalities, corporations and universities. It is expected that use of this tool to perform regular self-checks of brain health will become an opportunity to help the generation currently in their prime working years to gain a correct understanding of brain health and diseases, as well as to reconsider daily lifestyle, greater preventive measures, and consultation with doctors and other healthcare professionals.

For additional information, please visit https://nouknow.jp/. (Japanese only)
(List of partners: https://nouknow.jp/partner/

*The purpose of this tool is not to prevent or diagnose disease, but to raise awareness of brain health through regular checks.

Eisai will collaborate with local governments across Japan to create a community where citizens are aware of and check their brain health from the stage where they are healthy, aiming to realize a “Dementia-Inclusive Society” where everyone can live their lives how they would like.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120




Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
July 17, 2026 23:24 HKT/SGT
Marketing Authorization Application for In-house Developed Insomnia Drug Lemborexant Accepted for Evaluation by European Medicines Agency (EMA)
July 15, 2026 23:18 HKT/SGT
LEQEMBI(R) Real-World LEADER Study Presented at AAIC(R) 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
July 15, 2026 22:51 HKT/SGT
FDA Approves LEQEMBI IQLIK(R) (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
July 15, 2026 22:21 HKT/SGT
Eisai Presents Latest Findings Showed Etalanetug Reduced Alzheimer's Disease Tau Tangle-Specific Plasma Biomarker MTBR-tau243 at Alzheimer's Association International Conference(R) (AAIC(R)) 2026
July 13, 2026 23:06 HKT/SGT
LEQEMBI(R) Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference(R) (AAIC(R)) 2026
July 2, 2026 21:45 HKT/SGT
Eisai to Showcase Alzheimer's Disease Portfolio with More Than 50 Presentations at the Alzheimer's Association International Conference(R) 2026 (AAIC(R))
July 2, 2026 21:01 HKT/SGT
UCL and Eisai renew partnership to accelerate treatments for neurodegenerative diseases
June 17, 2026 12:28 HKT/SGT
Eisai Announces Strategic Investment Supported by the UK Government's LSIMF
May 21, 2026 23:23 HKT/SGT
Eisai Deepens Body of Clinical Evidence for LENVIMA(R) (Lenvatinib) Across Established Indications at ASCO 2026
Apr 21, 2026 19:52 HKT/SGT
Merck & Co., Inc., Rahway, NJ, USA and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
More news >>
 News Alerts
Copyright © 2026 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: